Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$87.28 USD

87.28
131,450

+1.16 (1.35%)

Updated May 10, 2024 04:00 PM ET

After-Market: $87.19 -0.09 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?

by Zacks Equity Research

Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.

Vanda (VNDA) Up on FDA Nod for Fanapt in Bipolar I Disorder

by Zacks Equity Research

Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.

EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia

by Zacks Equity Research

The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.

Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $73.60, marking a +0.68% move from the previous day.

Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $68.64, indicating a -0.88% shift from the previous trading day.

Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $73.11, indicating a +1.25% shift from the previous trading day.

Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.

Ligand Pharmaceuticals (LGND) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $73.77, marking a +1.79% move from the previous day.

Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now?

by Zacks Equity Research

Ligand (LGND) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.

Why Ligand Pharmaceuticals (LGND) Dipped More Than Broader Market Today

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reachead $72.37 at the closing of the latest trading day, reflecting a -1.75% change compared to its last close.

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -50.98% and 50.56%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Ligand Pharmaceuticals (LGND) Fell More Than Broader Market

by Zacks Equity Research

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $75.64, marking a -0.32% move from the previous day.

Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $74.72, denoting a +0.24% change from the preceding trading day.

Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $75.06, moving -1.82% from the previous trading session.

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed the most recent trading day at $73.39, moving +1.2% from the previous trading session.

Ligand Pharmaceuticals (LGND) Stock Moves -0.3%: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $70.86, denoting a -0.3% change from the preceding trading day.

Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed at $72.19 in the latest trading session, marking a -1.84% move from the prior day.

Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel

by Zacks Equity Research

Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.